First-of-its-kind patient cohort program announced at IPF Summit


A first-of-its-kind patient cohort platform will soon be available for UK and US researchers struggling to recruit patients with interstitial lung disease (ILD), such as pulmonary fibrosis and progressive fibrosis resulting from COVID -19. UK based company uMed announced the launch of the Access-ILD/PF cohort at the sixth annual Idiopathic Pulmonary Fibrosis (IPF) Summit in Boston.

uMed has developed technology that can quickly identify, directly engage and recruit patient populations at a significantly faster rate to participate in clinical and real-world studies.

“Research in the life sciences industry is often a long process, particularly in the area of ​​rare diseases, where it can take years,” said Matt Wilson, MD, Founder and Chairman of uMed. “Our pioneering platform is designed to solve the challenges facing researchers and patients – delays in new therapies.”

According to Dr. Wilson, the uMed platform links electronic medical records (EMRs) to hospitalization data, patient-reported outcomes, medical device data and even DNA sampling to identify cohorts of patients eligible to participate in various studies. These include clinical trials and prospective observational research. It is the only platform capable of synergistically linking these multiple health data points.

“Currently, there are over 200 clinical trials at various stages for ILD and PF/IPF,” Dr. Wilson noted. “With such a deep pipeline and more trials on the horizon, there is significant demand for patient involvement. This platform builds on the work we have successfully initiated in the UK, with the aim of creating a global cohort to support multiple studies.

“The tremendous advances we are seeing in the development of pulmonary fibrosis have resulted in several effective therapies,” added Fernando Martinez, MD, executive vice president of medicine at Weill Cornell Medical College and New York-Presbyterian Hospital/Weill Cornell Medical Center. “While there are many active studies ahead, a major limitation is identifying patients who would consider entering a clinical trial. uMed offers a very promising approach that could revolutionize the rapid completion of pivotal clinical studies for the patients.

Another unique aspect of the uMed platform is the inherent trust the company has built with physicians, allowing them to strategically partner, engage with their patients, and obtain consent. Currently, the uMed network covers over five million patients in the US and UK and will soon expand to Australia. The platform is HIPAA and GDPR compliant.

For more information on uMed’s unique platform or to see a demo, contact James Dunstan, VP Commercial at [email protected]+44 (0) 7488 812 678


uMed is a technology platform integrated with a global network of healthcare providers that automates the process of creating cohorts of prospective and protocol patients. This allows sites to participate in dozens of programs simultaneously without increasing overhead or staff workload. For life sciences companies, uMed provides access to research-grade real-world data, where patients from these datasets can be re-engaged in a compliant manner to support the goals of business and R&D teams. For more information, visit In November 2020, the company raised £3.7m in venture capital.

About Irene J. O'Donnell

Check Also

Gray Bruce’s virtual emergency care program is expanding

By Janice MacKay September 14, 2022 3:38 p.m. An expanded virtual emergency care program from …